At what enterprise value was INSTEM acquired in 2023?

During the acquisition of INSTEM by ARCHIMED in 2023, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M GBP. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the TMT (Tech, Media, Telecom) industry currently tracks an average EBITDA multiple of 14.5x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of INSTEM when it was acquired by ARCHIMED?

The estimated EV/EBITDA multiple for INSTEM is in the range of 15x - 25x. For comparison, the TMT (Tech, Media, Telecom) sector currently shows an average EBITDA multiple of 14.5x. Join our community for free to access full valuation data and industry trends.

When was INSTEM acquired by ARCHIMED?

INSTEM was acquired by ARCHIMED in 2023.

What was the revenue of INSTEM at the time of the deal?

The revenue of INSTEM at the time of the deal is estimated to be in the range of 50M - 100M GBP. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of INSTEM during the acquisition?

INSTEM's EBITDA is estimated to be in the range of 5M - 25M GBP. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the INSTEM acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the INSTEM deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.archimed.group/news/archimed-concludes-successfully-its-203-million-take-private-bid-for-drug-development-software-leader-instem/

← DATABASE

Home Database TMT (Tech, Media, Telecom)INSTEM

11/2023

INSTEM acquired by ARCHIMED

UNITED KINGDOM Software / Industry-Specific Software / Healthcare EV 100M - 350M GBP

Context

ARCHIMED has successfully completed the take-private acquisition of Instem, delisting the company from the London Stock Exchange (AIM). The transaction was driven by the need to liberate Instem from the short-term pressures of public reporting, allowing for more aggressive investment in long-term R&D. The strategic roadmap focuses on accelerating the adoption of "in silico" methods—using data and AI to model drug effects—which reduces the industry's reliance on animal testing and speeds up time-to-market. ARCHIMED intends to use Instem as a consolidation platform in the fragmented pre-clinical software market, leveraging its "MedTalents" network to source add-on acquisitions and drive international expansion.

INSTEM, which reported an EBITDA margin of in 2022, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the TMT (Tech, Media, Telecom) sector (14.5x).

-> Deep-dive in TMT (Tech, Media, Telecom) market trends

Target

Headquartered in Staffordshire, Instem is a leading provider of IT solutions for the global life sciences market. Its software suite is critical for the early stages of drug development (pre-clinical), helping pharmaceutical companies manage data, streamline workflows, and ensure regulatory compliance (specifically with the "SEND" standard mandated by the FDA). The company is also a pioneer in "in silico" simulation, using computer modeling to predict the toxicity and carcinogenicity of drugs before they are tested on animals or humans.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Software

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
12/2023	HG CAPITAL	VISMA GROUP	NORWAY	ERP, HR & Finance
12/2023	SEPTEO	SEQUOIASOFT	FRANCE	Travel & Hospitality
11/2023	PSG EQUITY	DIAPASON	FRANCE	ERP, HR & Finance
11/2023	OPTIMIZERX	MEDICX HEALTH	UNITED STATES	AdTech
11/2023	OCEANSOUND PARTNERS	MESSAGE BROADCAST	UNITED STATES	MarTech
11/2023	KEYSIGHT TECHNOLOGIES	ESI GROUP	FRANCE	Engineering & Design Software
11/2023	DEVOLVER DIGITAL	SYSTEM ERA SOFTWORKS	UNITED STATES	Gaming & Consumer Apps
11/2023	21 INVEST	CONEX	FRANCE	Industry-Specific Software
10/2023	CAPZA	TRAVELSOFT	FRANCE	Travel & Hospitality
10/2023	SANDVIK	ESCO	GERMANY	Supply Chain & Ops

REFERENCES

Valuation range: EV 100M - 350M GBP

Revenue range: 50M - 100M GBP

EBITDA range: 5M - 25M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of INSTEM by ARCHIMED are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: instem

Acquirer: archimed